Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

The UK Impact Transplant Trials Network: An Effective National Strategy to Accelerate the Delivery of Randomized Trials in Stem Cell Transplantation

Charles Craddock, David Marks, Victoria Potter, Wendy A Ingram, Rebecca Collings, Eleni Tholouli, Rachel Protheroe, Hugh Allen, Alex Ross, Dawn Farrar, Shamyla Siddique, Rebecca Bishop, Ronjon Chakraverty

Blood (2023) 142 (Supplement 1): 5097.

https://doi.org/10.1182/blood-2023-188490

Published: 2023

Journal Articles

Post-Transplant MRD Status and T Cell Chimerism Predict Outcomes in Patients Allografted for AML/MDS-a Prospective Analysis from the UK NCRI Figaro Trial

Blood (2021) 138 (Supplement 1): 415.

https://doi.org/10.1182/blood-2021-149269

Published: 2021

Journal Articles

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Blood (2019) 134 (Supplement_1): 2031.

https://doi.org/10.1182/blood-2019-125646

Published: 2019

Journal Articles

Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8 + T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial

Charlotte F Inman, BVSc, PhD, Suzy A Eldershaw, BSc. (Hons.), PhD, Hayden Pearce, BSc. (Hons.), PhD, Ben E Abbotts, BSc. (Hons.), MSc., Mirjana Sirovica, BSc(Hons), MSc, Paul Ferguson, MD PhD MRCP, Donna L Walsh, Dip(HE), BSc., Jane Nunnick, BSC. (Hons.), MSc., Shamyla Siddique, BSc.(Hons.), MPhil, Paul Moss, MBBS, PhD FRCP, Ram K Malladi, FRCPath

Blood (2017) 130 (Supplement 1): 1908.

https://doi.org/10.1182/blood.V130.Suppl_1.1908.1908

Published: 2017

Journal Articles

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Charles Craddock, Wendy Ingram, Daniel Slade, Andrea Hodgkinson, BSc(Hons),PhD, Francis J. Mussai, MA, MD DPhil, Carmela De Santo, Jamie Cavenagh, Michael Dennis, MDMRCP,FRCPath, Ram Malladi, MRCP, FRCPath, PhD, Shamyla Siddique, BSc.(Hons.), MPhil, Yap Christina, MSci, PhD CStat

Blood (2017) 130 (Supplement 1): 276.

https://doi.org/10.1182/blood.V130.Suppl_1.276.276

Published: 2017

Journal Articles

Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Charles Craddock, MD PhD, Aimee E Houlton, BSc, MSc, Paul Ferguson, MBChB MRCP PhD, Manoj Raghavan, Sonia Fox, Louise Dudley, BSc, MRes, Lynn Swun Quek, FRCPath, DPhil, MBBS, Jamie D. Cavenagh, Michael Dennis, FRCPath, Mary Frances McMullin, MD, Srinivas P Pillai, Richard Kelly, BSc, MD, Shamyla Siddique, Keith Wheatley, DPhil, Paresh Vyas, BM, DPhil, FRCP, FRCPath

Blood (2016) 128 (22): 1065.

https://doi.org/10.1182/blood.V128.22.1065.1065

Published: 2016

Journal Articles

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

Blood (2012) 119 (14): 3361–3369.

https://doi.org/10.1182/blood-2011-09-377044

Published: 2012

Includes: Supplemental data

Journal Articles

Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+ T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response

Mike Dennis, Oliver Goodyear, Justin Loke, Nadiria Jilani, Shamyla Siddique, Gordon Ryan, Rehela Khanum, John Snowden, Michael Griffiths, PhD, Nigel H. Russell, MD, John Yin, MD, Charles Crawley, MD, Gordon Cook, MD, PhD, Paresh Vyas, DPhil, FRCP, FRCPath, Paul AH Moss, MD PhD, Ram Malladi, Charles F. Craddock, BM, MRCP, MRCPath

Blood (2011) 118 (21): 324.

https://doi.org/10.1182/blood.V118.21.324.324

Published: 2011

Journal Articles

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia

Charles F. Craddock, MD PhD, Nicolas Goardon, PhD, Lynn Quek, MD, Sylvie Freeman, MD, PhD, Shamyla Siddique, Manoj Raghavan, Anna Schuh, PhD, David Grimwade, PhD, Robert K Hills, MA, MSc, DPhil, Cassandra Brookes, PhD, Michael Griffiths, PhD, James D. Cavenagh, MD, Ravindra Majeti, MD, PhD, Irving L. Weissman, MD, Alan K Burnett, MD, Paresh Vyas

Blood (2011) 118 (21): 638.

https://doi.org/10.1182/blood.V118.21.638.638

Published: 2011

Journal Articles

Induction of a CD8 + T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

Oliver Goodyear, Angelo Agathanggelou, Igor Novitzky-Basso, Shamyla Siddique, Tina McSkeane, Gordon Ryan, Paresh Vyas, Jamie Cavenagh, Tanja Stankovic, Paul Moss, Charles Craddock

Blood (2010) 116 (11): 1908–1918.

https://doi.org/10.1182/blood-2009-11-249474

Published: 2010

Includes: Supplemental data

Journal Articles

5′ Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.

Charles Craddock, BM, DPhil, FRCP, FRCPath, Nicolas Goardon, Mike Griffiths, James D. Cavenagh, MD, Shamyla Siddique, Paresh Vyas, BM, DPhil, FRCP, FRCPath

Blood (2008) 112 (11): 945.

https://doi.org/10.1182/blood.V112.11.945.945

Published: 2008

Journal Articles

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

Eduardo Olavarria, Shamyla Siddique, Michael J. Griffiths, Sharon Avery, Jenny L. Byrne, Karen P. Piper, Anne L. Lennard, Lalit Pallan, Julie M. Arrazi, Jolanta B. Perz, Derville O'Shea, John M. Goldman, Jane F. Apperley, Charles F. Craddock

Blood (2007) 110 (13): 4614–4617.

https://doi.org/10.1182/blood-2007-04-082990

Published: 2007

NARROW

The UK Impact Transplant Trials Network: An Effective National Strategy to Accelerate the Delivery of Randomized Trials in Stem Cell Transplantation

Post-Transplant MRD Status and T Cell Chimerism Predict Outcomes in Patients Allografted for AML/MDS-a Prospective Analysis from the UK NCRI Figaro Trial

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8 + T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+ T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia

Induction of a CD8 + T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

5′ Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only